AGC Inc
Vertically integrated industrial manufacturer across five segments (Architectural Glass, Automotive/Mobility, Electronics, Chemicals [Essential + Performance], Life Science CDMO); mix of commodity/cyclical volume businesses and high-barrier specialty franchises; JPY-reporting, globally sold, energy- and capex-intensive.
Earnings, margins, COGS & capex
FY2025 was a flat-revenue, modestly-higher-profit year: net sales JPY 2,058.8B (down JPY 8.8B, roughly flat), operating profit JPY 127.5B (+JPY 1.6B), and profit attributable to owners of JPY 69.2B — a JPY 163.2B positive swing from the FY2024 JPY 94B net loss, which had been driven by large impairments (notably Life Science / display). Quality of earnings is heavily FX-influenced: yen weakness (USD/JPY ~155-160 in FY2026 vs prior) is a major swing factor. Automotive turnaround (OP more than doubled to JPY 29.3B) and Chemicals resilience partly offset Electronics softness (weaker semiconductor-material shipments) and a persistent Life Science operating loss (JPY -22.3B). ROE remains low at 4.7%.
Revenue trend
Margins
flat-to-up; guided ~6.8% at FY2026 OP JPY 150B
swung positive from FY2024 net loss
up; guided 5.2% FY2026 — still below cost of equity
up from JPY 89.2B FY2024
COGS structure
Not separately disclosed; cost base is energy-intensive (glass melting furnaces, chlor-alkali electrolysis) and raw-material-heavy (silica sand, soda ash, salt, natural gas). European natural-gas prices are a swing input; declining EU gas prices were cited as a Q1 FY2026 profit tailwind.
Capex
Not separately disclosed for FY2025 in reviewed sources; capital allocation is being shifted TOWARD Electronics (semiconductor/EUV-related materials capacity) and AWAY from Chemicals and Life Science. Historically ~JPY 230-250B/yr. Dividend held at JPY 210/share.
Latest earnings
Beat consensus revenue; stock rose on the print
FY2026: net sales JPY 2,200B, operating profit JPY 150B (+JPY 22.5B), ROE 5.2%, Life Science loss narrowing to ~JPY -5B
- Q1 FY2026 profit to owners
- JPY 22.8B (+JPY 16.2B YoY)
- Primary Q1 profit driver
- Yen weakness / FX gains + EU gas-price decline + Chemicals volume (SE Asia)
- FY2026 OP guidance
- JPY 150B (+18% vs FY2025)
- Dividend
- JPY 210/share (held)
Growth drivers
- Semiconductor materials demand — EUV mask blanks, EUV/immersion process chemicals, and advanced-node materials scaling with ASML EUV scanner shipments and 2nm/High-NA ramp
- Automotive/Mobility recovery — higher volume/price/mix; EV and HUD/panoramic-roof glass raise content per vehicle
- Performance Chemicals — Fluon (ETFE/PTFE) fluoropolymers into architecture, semiconductors, EV batteries, and hydrogen membranes
- Life Science CDMO loss reduction (guided from JPY -22.3B FY2025 toward JPY -5B FY2026) as biologics/synthetic capacity utilization improves
- Yen weakness translating overseas earnings + boosting export competitiveness (double-edged: also a reported-figure inflator)
Bull & bear
A cheap, misunderstood conglomerate where a hidden semiconductor-materials + fluorochemicals franchise is buried inside cyclical glass and a fixable CDMO — trading near/below book at ~0.6x sales with a self-help margin and Life Science turnaround underway.
- Deep-value optics: ~$8.7B mcap on ~$13.7B revenue (~0.6x P/S), P/B near/below 1 — the market prices AGC as a commodity glassmaker, not as the EUV-mask-blank leader
- Real chokepoint: ~59% EUV mask-blank share in a business that scales with every EUV scanner ASML ships, with years-long qualification moats — a structural growth annuity inside a 'boring' name
- Self-help visible: FY2026 guidance lifts OP ~18% to JPY 150B, Automotive OP already more than doubled to JPY 29.3B, and Life Science loss is guided to shrink from JPY -22.3B toward JPY -5B
- Yen weakness + falling EU gas prices are near-term earnings tailwinds; balance sheet (D/E 0.37) funds a held JPY 210 dividend while it re-rates
- Sum-of-parts / activist optionality: separating or fixing the low-return commodity glass and CDMO would expose higher-multiple electronics + performance-chemicals earnings
A classic Japanese value trap: chronic sub-cost-of-equity ROE, earnings that rise on yen not operations, and a specialty franchise too small to move a ~JPY 2T revenue base dominated by cyclical, oversupplied glass and a CDMO that keeps losing money.
- ROE stuck at ~5% despite the 'turnaround' — capital is trapped in commodity glass and a Life Science unit that has burned money for years and already took large impairments in FY2024
- The good business is small: EUV mask blanks is only a few-hundred-$M end-market (est. ~$550M near-term, per-report); the Electronics segment (OP JPY 47.5B, and falling) can't offset the cyclical bulk of the company
- Earnings quality is poor — FY2025 profit swing and Q1 FY2026 growth were driven largely by FX and gas prices; a yen reversal unwinds the story
- Structural glass headwinds: Chinese float-glass oversupply and soft construction cap architectural-glass pricing indefinitely
- PFAS/fluorochemical regulation is a slow-moving threat to a key profit pool (Chemicals segment OP JPY 53.0B, incl. Performance)
What it is worth
Sum-of-parts / relative multiple, cross-checked vs low P/B and P/S — AGC is a break-up/re-rating story, not a growth compounder
Value trap: ROE stays sub-cost-of-equity, Life Science losses persist, yen reverses and EU gas spikes unwind reported profit, Chinese glass oversupply caps the cyclical base — the discount to book is deserved and persists.
Slow grind: FY2026 OP JPY 150B / ROE 5.2% delivered, modest multiple, value realized mostly via FX + cyclical recovery + dividend — stock tracks earnings, limited re-rating.
Re-rate toward/above book as Life Science turns, semiconductor-materials earnings compound, and self-help lifts ROE above cost of equity; SOTP/activist unlock of the specialty franchises implies meaningful upside from ~0.6x sales.
At ~$8.7B mcap on ~$13.7B revenue (~0.6x P/S) and P/B near/below 1 with ~5% ROE, the market prices AGC as a low-return cyclical glassmaker. The debate is whether the EUV-mask-blank + fluorochemical + electronics franchises are worth materially more than the whole once the commodity-glass + Life Science drag is fixed. Re-rating requires ROE moving toward/above cost of equity — guidance (5.2% FY2026) is a step, not a resolution. Not financial advice.
SWOT
Strengths
- Global #1 in EUV mask blanks (~59% share) and a top-tier supplier of advanced semiconductor/display materials — a genuine chokepoint franchise with multi-year qualification barriers
- Top-3 global scale in automotive and architectural glass, with worldwide manufacturing footprint
- Diversified across glass + chemicals + electronics + life science, smoothing single-cycle exposure
- Strong balance sheet (D/E 0.37) supporting through-cycle capex and a stable dividend
Weaknesses
- Persistently low ROE (~4.7-5.2%), likely below cost of equity — capital tied up in commodity glass and a loss-making CDMO
- Life Science segment has been structurally loss-making (JPY -22.3B FY2025, vs JPY -21.2B FY2024) with prior impairments
- Earnings quality is heavily FX-dependent; reported profit swings on yen rather than operations
- Energy-intensive cost base exposed to European natural-gas volatility
Opportunities
- EUV/High-NA and AI-datacenter semiconductor buildout lifting mask-blank + electronics-materials demand (EUV mask-blank market est. ~15% CAGR; size estimates vary widely across reports, ~$550M-1.4B by early 2030s)
- EV transition raising glass content (larger area, HUD, panoramic roofs) and fluoropolymer demand (batteries, hydrogen)
- Life Science turnaround / capacity utilization inflecting from loss toward breakeven
- Portfolio re-rating / sum-of-parts unlock if commodity/CDMO drag is fixed and specialty franchises are recognized
Threats
- Chinese float-glass oversupply pressuring architectural-glass pricing (Xinyi, CSG, Fuyao)
- Semiconductor capex cyclicality — Electronics OP already fell JPY 6.9B FY2025 (to JPY 47.5B) on weaker chip-material shipments
- Construction/auto demand cycles and a stronger yen reversing the recent tailwind
- Fluorochemical/PFAS regulatory tightening (Europe/US) threatening parts of the Performance Chemicals franchise
Moats, dependencies & bottlenecks
Moats
Requires ultra-low-thermal-expansion glass + 40+ precise Mo/Si layers + phase-defect density <0.1/cm2; multi-year fab qualification cycles; no credible near-term third entrant. AGC leads at ~59%, Hoya ~34%
Top-3 worldwide; scale/logistics moat, but commoditizing at the low end and pressured by Chinese float supply
Specialty ETFE/PTFE into semis, architecture, EV, hydrogen; process know-how, but PFAS regulatory overhang
Proprietary specialty-glass chemistry (display/low-CTE substrates) Materials IP overlaps competitor Corning; display glass is cyclical/price-competitive
Dependencies
Electronics OP fell JPY 6.9B FY2025 (to JPY 47.5B) on weaker chip-material shipments; tied to ASML/foundry capex
Architectural Glass volume/price cyclical; Europe + Asia exposed
Automotive/Mobility rides OEM build rates; EV mix a swing factor
Melting furnaces + electrolysis energy-intensive; EU gas decline was a Q1 FY2026 tailwind, a spike is a headwind
Reported profit swings materially on yen; recent yen weakness flattered FY2025-Q1 FY2026 results
Competitive/market Oversupply from Chinese producers pressures global architectural-glass pricing
Advantages
- Genuine semiconductor chokepoint in EUV mask blanks with years-long qualification moats
- Rare breadth: glass + chemicals + electronics + life science under one balance sheet
- Strong, lowly-levered balance sheet (D/E 0.37) funding through-cycle capex and dividend
- Fluoropolymer franchise levered to secular EV/hydrogen/semiconductor demand
- Improving self-help: Automotive turnaround + Life Science loss narrowing guided for FY2026
Weaknesses
- Chronic sub-cost-of-equity ROE (~4.7-5.2%)
- FX-dependent earnings quality — yen, not operations, drives the swings
- Loss-making Life Science segment with prior impairment history
- Commodity glass exposure to Chinese oversupply and construction cycles
- PFAS/fluorochemical regulatory risk to a key profit pool
Bottlenecks
- Life Science CDMO under-utilization keeping the segment loss-making (JPY -22.3B FY2025)
- Low corporate ROE (~5%) — capital efficiency, not demand, is the binding constraint
- Energy-cost and gas-price exposure on the commodity glass + chemicals base
- Cyclical/oversupplied architectural glass diluting the group multiple
- Specialty (electronics) franchise too small relative to the JPY 2T revenue base to re-rate the whole
Top signals & trends
Top signals
Management signaling a step-up, led by margin not just yen
Turnaround inflection — the biggest single drag narrowing
Volume/price/mix recovery sticking
The premium segment softened in FY2025
Low-quality driver; reverses if yen strengthens or gas spikes
Balance-sheet conservative; not yet returning the upside
Trends
Mask-blank + electronics-materials demand; EUV mask-blank market est. ~15% CAGR
Lifts advanced-node materials demand where AGC is a supplier
More/larger auto glass (HUD, panoramic roofs) + fluoropolymers into batteries
Structural pricing pressure on architectural glass
Threatens parts of Performance Chemicals
Positive (near-term) · Flatters reported earnings; a reversal is a risk, not a permanent tailwind
Ecosystem & competitor graph
Suppliers feed the company; customers pull from it. Line thickness shows the strength of each tie (supply-chain dependency, customer earnings contribution). Hover to isolate a tie.
Furnace + electrolysis energy — a key swing input cost
Core raw materials for glass and chlor-alkali
Ion-beam-deposition + actinic-inspection tool makers Capital equipment enabling EUV mask-blank precision
Leading-edge foundry consuming EUV masks/materials (via mask shops)
Foundry + display; semiconductor-material and display-glass customer
Advanced-node/EUV customer of the mask-blank supply chain
Photomask makers that pattern AGC blanks — the direct mask-blank customer layer
Automotive/Mobility glass buyers
LG Display, BOE) Display-glass substrate customers
Life Science contract biologics/synthetic-drug manufacturing customers
Direct rival in display/specialty glass and optical materials; higher-margin, higher-multiple US comp
Japanese flat + automotive glass direct competitor
Global building/architectural + auto glass leader
The other half of the EUV mask-blank duopoly (AGC leads ~59%, Hoya ~34%) + optics
Overlaps in semiconductor materials, PVC and silicones; far higher ROE/multiple
Chlor-alkali / caustic soda / epoxy competitor in Essential Chemicals
PVC / chlor-vinyls competitor
Fluoroproducts competitor to Performance Chemicals (Fluon)
Chinese float-glass giant driving architectural-glass oversupply (context only, not an own-call)
Dominant low-cost auto-glass maker pressuring Mobility (context only, not an own-call)